List view / Grid view
18 March 2014 | By Biogen Idec
Biogen Idec announced that the U.S. Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for its review of the Biologics License Application for marketing approval of PLEGRIDY...
5 March 2014 | By Biogen Idec
Agreement to enhance R&D capabilities and pipeline aimed at creating new therapies to suppress Alzheimer’s disease progression...
17 February 2014 | By Biogen Idec
Stelios Papadopoulos to become Chairman of the Board...
3 February 2014 | By Biogen Idec
Biogen Idec to begin launching TECFIDERA in initial EU Countries in the coming weeks...
30 January 2014 | By Biogen Idec
Relationship leverages UCB’s expertise and presence in Asia to bring Biogen Idec’s Innovative therapies to patients in new markets...
9 January 2014 | By Biogen Idec
“Our collaboration with Sangamo is expected to help us expand our capabilities to develop treatments for people with serious, inherited hematologic conditions..."
17 December 2013 | By Biogen Idec
Biogen Idec opts-in to commercialization opportunity with joint venture partner...
2 December 2013 | By Biogen Idec
Biogen Idec announced that the U.S. Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for its review of the Biologics License Application for ALPROLIX...
22 November 2013 | By Biogen Idec
This designation will provide 10 years of regulatory exclusivity for TECFIDERA in the European Union...
13 November 2013 | By Biogen Idec
Phase 3 study showed potential for once- or twice-weekly prophylactic dosing regimens...
4 October 2013 | By Biogen Idec
Interim results from ENDORSE extension study reinforce favorable safety profile in patients treated for up to six and a half years...
3 October 2013 | By Biogen Idec
“These analyses build upon a growing body of evidence that demonstrates greater clinical benefits for people with MS when TYSABRI is initiated earlier in the course of the disease..."
23 September 2013 | By Biogen Idec
More than 55 company-sponsored presentations underscore Biogen Idec’s commitment to treatment advances for people with MS...
9 September 2013 | By Biogen Idec
Biogen Idec and Isis Pharmaceuticals, Inc. announced that the companies have entered into a broad, multi-year collaboration...
19 July 2013 | By Biogen Idec
U.S. and EU regulatory authorities have accepted marketing applications...
